OPKO Health, Inc. Increase (Decrease) in Deferred Revenue
OPKO Health, Inc. (OPK) reported Increase (Decrease) in Deferred Revenue of -$58.88 million for the 12-month period ending 2017-12-31, per its 8-K filed 2019-01-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2019-01-29
- OPKO Health, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$16.73M, a 412.03% decline year-over-year.
- OPKO Health, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$8.12M.
- OPKO Health, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$16.66M.
- OPKO Health, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was -$17.36M.
- OPKO Health, Inc. increase (decrease) in deferred revenue for fiscal 2014 was $0.00.
- OPKO Health, Inc. increase (decrease) in deferred revenue for fiscal 2013 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | -$16.73M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | -$24.86M derived: sum of 2 quarters · filed 2019-01-29 | -$41.52M derived: sum of 3 quarters · filed 2019-01-29 | -$58.88M 8-K · filed 2019-01-29 | -$60.66M 10-K · filed 2018-03-01 |
| 2017-09-30 | -$8.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$24.79M derived: sum of 2 quarters · filed 2017-11-08 | -$42.14M 10-Q · filed 2017-11-08 | -$36.78M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2017-06-30 | -$16.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$34.02M 10-Q · filed 2017-08-08 | -$28.66M derived: sum of 3 quarters · filed 2019-01-29 | -$48.97M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2017-03-31 | -$17.36M 10-Q · filed 2017-05-10 | -$11.99M derived: sum of 2 quarters · filed 2019-01-29 | -$32.31M derived: sum of 3 quarters · filed 2019-01-29 | -$50.44M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2016-12-31 | $5.36M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | -$14.96M derived: sum of 2 quarters · filed 2019-01-29 | -$33.08M derived: sum of 3 quarters · filed 2019-01-29 | -$50.89M 8-K · filed 2019-01-29 | -$74.17M 10-K · filed 2017-03-01 |
| 2016-09-30 | -$20.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$38.45M derived: sum of 2 quarters · filed 2017-11-08 | -$56.26M 10-Q · filed 2017-11-08 | -$52.75M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2016-06-30 | -$18.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$35.94M 10-Q · filed 2017-08-08 | -$32.43M derived: sum of 3 quarters · filed 2019-01-29 | -$50.09M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2016-03-31 | -$17.81M 10-Q · filed 2017-05-10 | -$14.30M derived: sum of 2 quarters · filed 2019-01-29 | -$31.96M derived: sum of 3 quarters · filed 2019-01-29 | -$50.28M derived: sum of 4 quarters · filed 2019-01-29 | |
| 2015-12-31 | $3.51M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | -$14.16M derived: sum of 2 quarters · filed 2019-01-29 | -$32.47M derived: sum of 3 quarters · filed 2019-01-29 | $249.77M 8-K · filed 2019-01-29 | $227.67M 10-K · filed 2016-02-29 |
| 2015-09-30 | -$17.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$35.98M derived: sum of 2 quarters · filed 2016-11-07 | $246.26M 10-Q · filed 2016-11-07 | $246.26M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | -$18.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $263.93M 10-Q · filed 2016-08-08 | $263.93M derived: sum of 3 quarters · filed 2017-03-01 | $264.77M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $282.24M 10-Q · filed 2016-05-09 | $282.24M derived: sum of 2 quarters · filed 2017-03-01 | $283.08M derived: sum of 3 quarters · filed 2017-03-01 | $282.28M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $846.00K derived: sum of 2 quarters · filed 2017-03-01 | $46.00K derived: sum of 3 quarters · filed 2017-03-01 | $0.00 10-K · filed 2017-03-01 | |
| 2014-09-30 | $846.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $46.00K derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | -$800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$846.00K 10-Q · filed 2015-08-05 | |||
| 2014-03-31 | -$46.00K 10-Q · filed 2015-05-11 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |